SEY1 Antibody

Basic Research Questions

• What is SEY1 and why would researchers need antibodies against it?

SEY1 (Synthetic Enhancer of YOP1) is a dynamin-like GTPase that plays a crucial role in homotypic endoplasmic reticulum (ER) membrane fusion. It functions analogously to mammalian atlastins (ATLs) in mediating ER fusion through a mechanism that involves GTP binding and hydrolysis . SEY1 has been identified in various organisms including Saccharomyces cerevisiae and Plasmodium falciparum, where it appears to be essential for normal cellular function .

Researchers require antibodies against SEY1 for several important applications:

• Investigating SEY1 localization and expression patterns within the tubular ER network

• Studying protein-protein interactions between SEY1 and ER-shaping proteins like Rtn1p and Yop1p

• Analyzing structural changes in SEY1 during GTP binding and hydrolysis cycles

• Examining SEY1's role in pathogenic organisms like Plasmodium, where it has been identified as a potential drug target

• Validating genetic manipulation experiments targeting SEY1

In Plasmodium research specifically, SEY1 has been identified as an essential gene and a novel druggable target, making antibodies against this protein particularly valuable for both basic research and potential therapeutic development .

• What are the key structural domains of SEY1 that antibodies might target?

SEY1 consists of several distinct structural domains that could serve as targets for antibody development:

The GTPase domain represents an attractive target due to its functional importance and the presence of conserved motifs . When generating antibodies against SEY1, researchers should consider whether they want an antibody that recognizes SEY1 across multiple species (targeting conserved regions) or one that is species-specific (targeting variable regions). The helical bundle domain of SEY1 is notably longer than that of atlastins, which might provide unique epitopes for antibody recognition .

• How is SEY1 conserved across different species, and what implications does this have for antibody development?

SEY1 shows significant conservation across diverse species, particularly within its functional GTPase domain. This conservation pattern has important implications for antibody development:

For antibody development, this conservation pattern suggests:

• Antibodies targeting highly conserved regions of the GTPase domain might cross-react across species, which could be advantageous for comparative studies but problematic for species-specific investigations.

• For species-specific antibodies, researchers should target unique regions of SEY1 that diverge across species, such as the helical bundle domain or C-terminal regions.

• Researchers studying mammalian systems should note that mammals use atlastins rather than SEY1 for ER membrane fusion. While functionally analogous, these proteins are structurally distinct, so antibodies against SEY1 would not be expected to recognize atlastins .

• What experimental methods can be used to validate the specificity of SEY1 antibodies?

Validating the specificity of SEY1 antibodies requires multiple complementary approaches to ensure reliable experimental results:

• Western Blot Validation:

  • Compare detection in wild-type samples versus SEY1 knockout/knockdown samples

  • Confirm band detection at the expected molecular weight (approximately 80-110 kDa depending on species)

  • Perform peptide competition assays where the antibody is pre-incubated with the immunizing peptide

  • Include positive controls from recombinant SEY1 expression systems, such as the SEY1-TAP and SEY1-myc constructs described in the literature

• Immunoprecipitation (IP) Validation:

  • Perform IP followed by mass spectrometry to confirm the identity of pulled-down proteins

  • Conduct reciprocal IP experiments with antibodies targeting different epitopes of SEY1

  • Compare results between wild-type and SEY1-depleted samples

  • Verify the ability to co-immunoprecipitate known interaction partners like Rtn1p and Yop1p

• Immunofluorescence Validation:

  • Confirm localization to the tubular ER network, consistent with SEY1's known distribution

  • Perform co-localization studies with established ER markers

  • Include SEY1 knockout/knockdown controls to demonstrate staining specificity

  • Use ultrastructure expansion microscopy to visualize detailed ER morphology changes

• Genetic Validation Approaches:

  • Express tagged versions of SEY1 (e.g., SEY1-GFP) and confirm co-detection with the antibody

  • Test antibody reactivity in samples with SEY1 mutations in the target epitope

  • Utilize the SEY1 overexpression systems described in research to confirm antibody sensitivity

• Functional Validation:

  • For antibodies targeting the GTPase domain, assess their ability to inhibit GTP hydrolysis activity

  • Compare antibody effects with known SEY1 functional mutations (e.g., SEY1-K50A)

Advanced Research Questions

• How can researchers design antibodies that specifically distinguish between SEY1 and other dynamin-like GTPases?

Designing antibodies with high specificity for SEY1 over other dynamin-like GTPases requires sophisticated approaches to epitope selection and validation:

• Sequence-Based Epitope Selection:

  • Perform comprehensive sequence alignments between SEY1 and other dynamin-like GTPases

  • Identify regions unique to SEY1, particularly outside the highly conserved GTPase motifs

  • Target the helical bundle domain, which is significantly longer in SEY1 than in atlastins, providing potentially unique epitopes

  • Focus on the C-terminal region which typically shows higher sequence divergence

• Structural Analysis for Epitope Accessibility:

  • Utilize structural data (e.g., crystal structure of Candida albicans SEY1) to identify surface-exposed regions

  • Target loops or regions with high surface accessibility

  • Avoid transmembrane regions which are less accessible in native protein

• Advanced Immunization and Screening Strategies:

  • Use multiple peptides from different regions of SEY1 for immunization

  • Implement multi-step screening protocols that include counter-selection against other dynamin-like GTPases

  • Apply phage display technology with negative selection steps against related GTPases

  • Utilize computational approaches similar to those described for antibody specificity profiling to design antibodies with customized specificity profiles

• Validation in Complex Biological Samples:

  • Test antibody specificity in samples overexpressing various dynamin-like GTPases

  • Validate in tissues or cells from SEY1 knockout models

  • Compare reactivity between wild-type SEY1 and the GTPase-dead mutant (SEY1-K50A)

  • Assess cross-reactivity with atlastins in mammalian samples

• What are the optimal experimental conditions for using SEY1 antibodies in different assays?

Optimizing experimental conditions for SEY1 antibodies requires consideration of the protein's properties and specific assay requirements:

Additional optimization considerations:

• GTP State Sensitivity:

  • SEY1's conformation changes depending on GTP binding status

  • Some antibodies may preferentially recognize specific nucleotide-bound states

  • For comprehensive detection, test antibody recognition under different nucleotide conditions

  • Consider including non-hydrolyzable GTP analogs to stabilize specific conformations

• Membrane Protein Extraction Challenges:

  • SEY1 contains transmembrane domains that anchor it to the ER

  • For western blots, avoid boiling samples as this can cause aggregation

  • Use mild detergents for extraction while maintaining native conformation

  • Consider digitonin for preserving protein-protein interactions during immunoprecipitation

• Species-Specific Considerations:

  • Antibodies raised against yeast Sey1p may require different conditions than those against Plasmodium SEY1

  • When working with Plasmodium, special parasite lysis buffers may be necessary

  • Validate optimal conditions for each species being studied

• How might antibodies be used to investigate SEY1's role in ER membrane fusion?

Antibodies provide powerful tools for investigating SEY1's role in ER membrane fusion through multiple experimental approaches:

• Functional Inhibition Studies:

  • Use antibodies targeting the GTPase domain to inhibit SEY1 function

  • Microinject function-blocking antibodies into cells and observe effects on ER morphology

  • Compare results with GTPase-deficient SEY1 mutants (e.g., SEY1-K50A) to confirm specificity

  • Quantify changes in ER tubular network formation using fluorescence microscopy

• Dimerization and Conformational Studies:

  • Develop conformation-specific antibodies that recognize different states of SEY1 (GTP-bound, transition state, GDP-bound)

  • Use these antibodies to track conformational changes during the GTPase cycle

  • Perform immunoprecipitation under different nucleotide conditions to capture SEY1 interacting partners

  • Implement proximity assays to detect SEY1 dimerization events in situ

• In vitro Reconstitution Systems:

  • Use antibodies to inhibit specific steps in the in vitro fusion assay described in the literature

  • Apply antibodies to proteoliposomes containing purified SEY1 to determine which epitopes are critical for fusion

  • Create antibody-based systems to trap specific intermediate states during the fusion process

  • Study the GTP-dependent fusion of proteoliposomes in the presence or absence of inhibitory antibodies

• Redundancy Mechanism Investigation:

  • Research has identified a second, ER SNARE-mediated fusion mechanism that is redundant with SEY1

  • Use antibodies against both SEY1 and Ufe1p (the ER SNARE) to investigate the interplay between these pathways

  • Perform double-inhibition experiments to understand compensatory mechanisms

  • Track changes in protein expression and localization when one pathway is inhibited

• ER Morphology Analysis:

  • Use ultrastructure expansion microscopy with SEY1 antibodies to examine changes in ER and Golgi morphology following GNF179 treatment, as described in recent research

  • Correlate SEY1 localization with ER fusion sites using dual-color imaging

  • Examine how antibody inhibition affects ER network formation in the presence or absence of ER-shaping proteins like Rtn1p and Yop1p

• What approaches can be used to generate and validate antibodies against specific domains of SEY1?

Generating domain-specific antibodies against SEY1 requires specialized approaches to ensure specificity and functionality:

• Domain-Specific Antigen Design Strategies:

• Advanced Immunization Approaches:

  • For GTPase domain antibodies, use both active site and allosteric site peptides

  • Employ DNA immunization for conformationally intact domains

  • Use prime-boost strategies with different antigen forms

  • Consider liposome-displayed antigens to mimic membrane environment

• Recombinant Antibody Technologies:

  • Apply phage display with domain-specific selection strategies

  • Implement computational models to predict antibody specificity profiles, similar to approaches described for other antibody development

  • Use yeast display for fine-tuning binding affinity and specificity

  • Consider developing antibodies similar to the LAIR1-containing antibodies described in the literature for other applications

• Functional Validation Methods:

  • For GTPase domain antibodies, test effects on GTP hydrolysis rates in vitro, similar to the GNF179 inhibition of PvSEY1 GTPase activity

  • For helical bundle antibodies, examine impact on conformational changes

  • For antibodies targeting interaction interfaces, assess disruption of protein-protein interactions with Rtn1p and Yop1p

  • Compare antibody effects with known domain-specific mutations (e.g., the K50A mutation in the GTPase domain)

• Domain-Specific Validation Techniques:

  • Express individual domains as fusion proteins for epitope mapping

  • Perform mutagenesis of key residues in each domain to confirm epitope specificity

  • Use the SEY1 overexpression systems described in research to validate antibody sensitivity to increased protein levels

  • Test antibodies in the in vitro proteoliposome fusion system to determine effects on function

• How can researchers use antibodies to study SEY1's interactions with other proteins like Yop1p and Rtn1p?

Antibodies provide valuable tools for investigating SEY1's protein-protein interactions, particularly with ER-shaping proteins:

• Co-immunoprecipitation (Co-IP) Approaches:

  • Use anti-SEY1 antibodies for IP followed by western blotting for Yop1p and Rtn1p

  • Perform reverse Co-IP with anti-Yop1p or anti-Rtn1p antibodies to confirm interactions

  • Compare results under different nucleotide conditions (GTP, GDP, non-hydrolyzable analogs)

  • Research has established that SEY1 interacts physically with Rtn1p and Yop1p, which are homologues of the reticulons and DP1 respectively

• Interaction Domain Analysis:

  • Generate a panel of domain-specific SEY1 antibodies

  • Test which antibodies compete with or enhance interactions with Yop1p/Rtn1p

  • Use epitope-specific antibodies to block particular interfaces and assess functional consequences

  • Examine how these interactions affect the ability of Sey1p to restore the tubular ER network in sey1Δ yop1Δ cells

• Functional Consequence Assessment:

  • Use interaction-blocking antibodies and measure effects on ER morphology

  • Compare the effects of antibody inhibition with genetic mutations in interaction interfaces

  • Assess how disrupting specific interactions affects ER fusion efficiency

  • Investigate the synthetic genetic interaction between SEY1 and YOP1 that gave SEY1 its name (Synthetic Enhancer of YOP1)

• In vivo Imaging Approaches:

  • Perform triple-labeling immunofluorescence to visualize SEY1, Yop1p, and Rtn1p simultaneously

  • Use super-resolution or expansion microscopy for detailed co-localization analysis

  • Track the distribution of these proteins during ER fusion events

  • Analyze how the distribution pattern changes in mutant backgrounds (e.g., sey1Δ yop1Δ cells)

• Cross-Species Comparative Analysis:

  • Compare interaction patterns between SEY1-Yop1p-Rtn1p in yeast and their homologs in other species

  • Use antibodies against conserved epitopes to study evolutionary conservation of these interactions

  • Apply the information about ATL1 substitution for SEY1 to study conservation of interaction networks

  • Examine whether the relationship between these proteins is maintained in Plasmodium

• What considerations should be made when designing antibodies against Plasmodium SEY1 as a potential therapeutic target?

Designing antibodies against Plasmodium SEY1 for therapeutic purposes involves specialized considerations that bridge basic research and translational applications:

• Target Domain Selection:

  • Focus on the GTPase domain, which research has identified as druggable and essential for parasite viability

  • Recent studies show that GNF179 binds to recombinant Plasmodium SEY1 and inhibits its GTPase activity, suggesting this domain is a viable therapeutic target

  • Target Plasmodium-specific epitopes that differ from human dynamin-like GTPases to minimize cross-reactivity

  • Consider regions involved in the parasite-specific functions of SEY1

• Specificity Engineering:

  • Design antibodies that specifically target Plasmodium SEY1 without cross-reactivity to human proteins

  • Apply computational approaches for designing antibodies with customized specificity profiles

  • Test extensively for cross-reactivity against human tissues

  • Consider leveraging the structural conservation data showing mirror symmetry between PfSEY1 and CaSEY1

• Functional Inhibition Strategies:

  • Target the GTPase domain with emphasis on the conserved motifs (P-loop, Walker A, Walker B, and guanosine-binding sites)

  • Design antibodies that mimic or enhance the binding mode of GNF179, which has been shown to bind PfSEY1 and reduce its melting temperature

  • Create antibodies that lock SEY1 in specific conformational states to prevent GTPase cycling

  • Consider approaches that would disrupt ER morphology, which changes following GNF179 treatment

• Resistance Mitigation:

  • Target highly conserved epitopes essential for SEY1 function

  • Design antibody cocktails targeting multiple epitopes simultaneously

  • Consider the research finding that Plasmodium SEY1 overexpression confers resistance to GNF179

  • Target both SEY1 and alternative pathways to minimize resistance development

• Life Cycle Stage Considerations:

  • Research indicates that antimalarials that inhibit growth at all stages of the parasite life cycle would be ideal for eradication efforts

  • Determine which parasite life stages are most dependent on SEY1 function

  • Design stage-specific targeting strategies based on SEY1 expression patterns

  • Consider combination approaches targeting SEY1 across multiple life cycle stages

• Delivery and Format Optimization:

  • Evaluate different antibody formats (IgG, Fab, scFv) for optimal efficacy

  • Consider engineering bispecific antibodies that target both SEY1 and other Plasmodium proteins

  • Explore antibody-drug conjugates with GNF179 or related compounds

  • Investigate novel antibody approaches such as those utilizing inserted domains, similar to the LAIR1-containing antibodies described for other applications